You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Expansion and validation of novel mobile app for guiding home modifications for aging in place

    SBC: HomesRenewed Ventures LLC            Topic: R

    PROJECT SUMMARY In this Phase II SBIR, HomesRenewed Ventures, LLC (HRV Washington, DC) will build on our previous efforts to expand and validate an interactive mobile application (APP) for guiding home modifications (environmental interventions) critical to Aging in Place (AiP). Home modifications (HM) are associated with falls preventions, improved activities of daily living (ADLs), and emotional ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A Disease-Modifying Protein Therapeutic for the Treatment of COPD

    SBC: VERRA THERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARY Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide at 3.23 million (2019), while nearly 400 million suffer its effects. COPD is a heterogeneous, multi-phenotypic disease with lung damage derived from smoking, vaping, cooking, forest fires, pollution, chemical exposure, and numerous occupational hazards (e.g., 1st responders, military, agricul ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

    SBC: NUVOX PHARMA, L.L.C.            Topic: NINDS

    ABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms

    SBC: NEUROVASCULAR DIAGNOSTICS, INC.            Topic: 103

    Project SummaryIntracranial aneurysm (IA) rupture is the primary cause of non-traumatic subarachnoid hemorrhage, a catastrophic event that carries high rates of mortality (rt50%) and permanent disability (rt50% among survivors). When an unruptured IA is discovered, clinicians face the difficult decision of whether or not it should be treated. Since rupture rates are low (risk of rupture ~ 0.5-1% p ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Non-Clinical Pharmacology of CX-01

    SBC: Ceramedix Holding, LLC            Topic: NIAID

    Development of radiation medical countermeasures (MCM) has become a national security priority owing to such threats as radiological dispersal devices (i.e., “dirty bomb”) and nuclear accidents, which may be caused by extreme weather (such as occurred in Fukushima, Japan in 2011). Radiation exposure can be potentially lethal via the hematopoietic-acute radiation syndrome (H-ARS) and the gastro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia

    SBC: Haima Therapeutics LLC            Topic: NHLBI

    Project Summary/Abstract The normal platelet count in human blood is 150,000-400,000/μL, and these platelets are responsible for efficient hemostatic surveillance and bleeding mitigation in the body. Thrombocytopenia (TCP, low platelet count) is a condition caused by a decrease in platelet production, increase in platelet destruction or consumption, or increase in splenic sequestration. The age-a ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Enabling Toxoplasma gondii Kinome Directed Drug Discovery

    SBC: LUCEOME BIOTECHNOLOGIES, L.L.C.            Topic: NIAID

    Project Summary Toxoplasma gondii (T.gondii), the causative agent for toxoplasmosis, invades host cells through ingestion of uncooked infected meat or contaminated water. T.gondii infects 30% of the world’s population and the current cost of the disease in US itself is estimated to be $3B and rising. Current treatment regimen is effective only against acute infection and has severe side effects. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating

    SBC: Halomine Inc.            Topic: NIAID

    Project Summary/Abstract In the US, about 1.7 million Healthcare-Associated Infections (HAls) occur in hospitals each year, resulting in 99,000 deaths and an estimated $20 billion in healthcare costs. According to previous reports, as much as one third of HAI cases can be attributed to environmental surfaces, namely “high touch” surfaces (e.g., bed rails, machine buttons, equipment), in hospit ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a novel EEG-based index for evaluating amyloid and tau burden in Alzheimer's Disease

    SBC: Spark Neuro Inc.            Topic: NIA

    PROJECT SUMMARY Alzheimer’s disease (AD) is a progressive, neurodegenerative condition that impacts 44 million people globally. It is the most common cause of dementia—accounting for 80% of all dementia diagnoses—and predominantly affects older people. To date, AD has no cure. Thus, it is imperative to diagnose patients as early as possible to maximize the efficacy of symptom management stra ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. In vivo high-definition 3D corneal imaging

    SBC: LighTopTech Corp.            Topic: NEI

    The cornea, the outermost window of our visual system, is vulnerable to various types of infections and diseases. Corneal disease is one of the leading causes of visual deficiency and blindness, and is considered the second major cause of blindness in developing countries. There are nearly 5 million bilaterally corneal blind persons worldwide, and an estimated 23 million people affected by unilate ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government